Abstract
Loss of the tumor suppressive effect of transforming growth factor-β (TGF-β) has been commonly found at later stages in carcinogenic progression. Although the genes encoding TGF-β receptors and Smads have been found genetically altered in certain human cancers, no mutation in Smad3 has been observed. Therefore, suppression of Smad3 expression may mediate key oncogenic properties of TGF-β. First, we observed that 37.5% of human gastric cancer tissues showed low to undetectable levels of Smad3 and that in nine human gastric cancer cell lines examined, two showed deficient Smad3 expression. Introduction of Smad3 into human gastric cancer cells that did not express Smad3, restored TGF-β responsiveness: induction of p21 and p15 gene expression, and growth inhibition in response to TGF-β. Furthermore, these Smad3-expressing cells showed markedly decreased and delayed tumorigenicity in vivo. These findings suggest that Smad3 expression may have a critical role in tumor suppression in the early stages of gastric carcinogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K and Kawabata M . (1999). J. Biol. Chem., 274, 35269–35277.
Birchmeier W and Behrens J . (1994). Biochim. Biophys. Acta, 1198, 11–26.
Blobe GC, Schiemann WP and Lodish HF . (2000). N. Engl. J. Med., 342, 1350–1358.
Bouck N, Stellmach V and Hsu SC . (1996). Adv. Cancer Res., 69, 135–174.
Calonge MJ and Massagué J . (1999). J. Biol. Chem., 274, 33637–33643.
Chang J, Park K, Bang YJ, Kim WS, Kim D and Kim S-J . (1997). Cancer Res., 57, 2856–2859.
Christofori G and Semb H . (1999). Trends Biochem. Sci., 24, 73–76.
Dameron KM, Volpert OV, Tainsky MA and Bouck N . (1994). Science, 265, 1582–1584.
Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y and Wang X-F . (1999). Mol. Cell. Biol., 19, 2495–2504.
de Caestecker MP, Piek E and Roberts AB . (2000). J. Natl. Cancer Inst., 92, 1388–1402.
Derynck R, Zhang Y and Feng XH . (1998). Cell, 95, 737–740.
Derynck R, Akhurst RJ and Balmain A . (2001). Nat. Genet., 29, 117–129.
Fearon ER and Vogelstein B . (1990). Cell, 61, 759–767.
Fink SP, Swinler SE, Lutterbaugh JD, Massagué J, Thiagalingam S, Kinzler KW, Vogelstein B, Willson JK and Markowitz S . (2001). Cancer Res., 61, 256–260.
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D and Birchmeier W . (1991). J. Cell. Biol., 113, 173–185.
Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A and Reeve AE . (1998). Nature, 392, 402–405.
Hahm K-B, Cho K, Lee C, Im Y-H, Choi S-G, Sorensen PHB, Thiele CJ and Kim S-J . (1999). Nat. Genet., 23, 222–227.
Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE . (1996). Science, 271, 350–353.
Hanahan D and Folkman J . (1996). Cell, 86, 353–364.
Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K and Ito Y . (1999). J. Biol. Chem., 274, 31577–31582.
Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, Sato K and Hamada K . (1999). Cancer Res., 59, 3783–3789.
Heldin CH, Miyazono K and ten Dijke P . (1997). Nature, 390, 465–471.
Hirohashi S . (1998). Am. J. Pathol., 153, 333–339.
Ito Y and Miyazono K . (2003). Curr. Opin. Genet. Dev., 13, 43–47.
Jong HS, Lee HS, Kim TY, Im YH, Park JW, Kim NK and Bang YJ . (2002). Biochem. Biophys. Res. Commun., 292, 383–389.
Kang SH, Bang YJ, Jong HS, Seo JY, Kim NK and Kim S-J . (1999). Br. J. Cancer, 80, 1144–1149.
Keller G . (2002). Pathologica, 94, 229–233.
Kieser A, Weich HA, Brandner G, Marme D and Kolch W . (1994). Oncogene, 9, 963–969.
Kim S-J, Im Y-H, Markowitz SD and Bang Y-J . (2000). Cytokine Growth Factor Rev., 11, 159–168.
Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K and Hirai H . (1998). Nature, 394, 92–96.
Lee DK, Kim BC, Brady JN, Jeang KT and Kim S-J . (2002a). J. Biol. Chem., 277, 33766–33775.
Lee DK, Kim BC, Kim IY, Cho EA, Satterwhite DJ and Kim S-J . (2002b). J. Biol. Chem., 277, 38557–38564.
Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y . (2000). Cell, 109, 113–124.
Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S and Zhou Q . (1999). Genes Dev., 13, 2196–2206.
Markowitz S, Wang J, Meyeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M and Willson JKV . (1995). Science, 268, 1336–1338.
Massagué J . (1998). Annu. Rev. Biochem., 67, 753–791.
Massagué J and Chen YG . (2000). Genes Dev., 14, 627–644.
Massagué J and Wotton D . (2000). EMBO J., 19, 1745–1754.
Moses HL and Serra R . (1996). Curr. Opin. Genet. Dev., 6, 581–586.
Mukhopadhyay D, Tsiokas L and Sukhatme VP . (1995). Cancer Res., 55, 6161–6165.
Müller N, Reinacher-Schick A, Baldus S, van Hengel J, Berx G, Baar A, van Roy F, Schmiegel W and Schwarte-Waldhoff I . (2002). Oncogene, 21, 6049–6058.
Myeroff LL, Parsons R, Kim S-J, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, Bang Y-J, Lee HY, Park J-G, Lynch HT, Roberts AB, Vogelstein B and Markowitz SD . (1995). Cancer Res., 55, 5545–5547.
Park K, Kim S-J, Bang YJ, Park JG, Kim NK, Roberts AB and Sporn MB . (1994). Proc. Natl. Acad. Sci. USA, 91, 8772–8776.
Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng C, Kucherlapati R, Bottinger EP and Roberts AB . (2001). J. Biol. Chem., 276, 19945–19953.
Powell SM, Harper JC, Hamilton SR, Robinson CR and Cummings OW . (1997). Cancer Res., 57, 4221–4224.
Riggins GJ, Kinzler KW, Vogelstein B and Thiagalingam S . (1997). Cancer Res., 57, 2578–2580.
Roberts AB and Sporn MB . 1990. Peptide Growth Factors and their Receptors, Sporn MB and Roberts AB ( eds ). Spinger-Verlag: Heidelberg, Germany, pp. 419–472.
Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Luttges J, Kloppel G, Graeven U, Eilert-Micus C, Hintelmann A and Schmiegel W . (2000). Proc. Natl. Acad. Sci. USA, 97, 9624–9629.
Schutte M . (1999). Ann. Oncol., 4 (Suppl.), 56–59.
Shattuck T.M, Costa J, Bernstein M, Jensen RT, Chung DC and Arnold A . (2002). J. Clin. Endocrinol. Metab., 87, 3911–3914.
Shitara Y, Yokozaki H, Yasui W, Takenoshita S, Kuwano H, Nagamachi Y and Tahara E . (1999). Jpn. J. Clin. Oncol., 29, 3–7.
Sood R, Talwar-Trikha A, Chakrabarti SR and Nucifora G . (1999). Leukemia, 13, 348–357.
Takagi Y, Koumura H, Futamura M, Aoki S, Ymaguchi K, Kida H, Tanemura H, Shimokawa K and Saji S . (1998). Br. J. Cancer, 78, 1152–1155.
Takenoshita S, Tani M, Mogi A, Nagashima M, Nagamachi Y, Bennett WP, Hagiwara K, Harris CC and Yokota J . (1998). Carcinogenesis, 19, 803–807.
Vleminckx K, Vakaet Jr L, Mareel M, Fiers W and van Roy F . (1991). Cell, 66, 107–119.
Wakefield LM and Roberts AB . (2002). Curr. Opin. Genet. Dev., 12, 22–29.
Wall NA and Hogan BL . (1994). Curr. Opin. Genet. Dev., 4, 517–522.
Weinstein M, Monga SP, Liu Y, Brodie SG, Tang Y, Li C, Mishra L and Deng CX . (2001). Mol. Cell. Biol., 21, 5122–51231.
Xiangming C, Natsugoe S, Takao S, Hokita S, Ishigami S, Tanabe G, Baba M, Kuroshima K and Aikou T . (2001). Clin. Cancer Res., 7, 277–282.
Yanagisawa K, Uchida K, Nagatake M, Masuda A, Sugiyama M, Saito T, Yamaki K, Takahashi T and Osada H . (2000). Oncogene, 19, 2305–2311.
Yang H-K, Kang SH, Kim Y-S, Won K, Bang Y-J and Kim S-J . (1999). Oncogene, 18, 2213–2219.
Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB and Deng CX . (1999). EMBO J., 18, 1280–1291.
Zawel L, Daim JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B and Kern SE . (1998). Mol. Cell, 1, 611–617.
Zhu Y, Richardson JA, Parada LF and Graff JM . (1998). Cell, 94, 703–714.
Acknowledgements
We thank A Roberts for critical reading of the manuscript, M Lewis for the preparation of the manuscript, K Miyazono for Smad3 construct, J Massagué for 3TP-Lux reporter, and S Kern for SBE-luc reporter.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Han, SU., Kim, HT., Seong, D. et al. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 23, 1333–1341 (2004). https://doi.org/10.1038/sj.onc.1207259
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207259
Keywords
This article is cited by
-
microRNA-17 functions as an oncogene by downregulating Smad3 expression in hepatocellular carcinoma
Cell Death & Disease (2019)
-
PD-1 and cancer: molecular mechanisms and polymorphisms
Immunogenetics (2018)
-
FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis
Nature Communications (2017)
-
Establishment of a gastric cancer subline with high metastatic potential using a novel microfluidic system
Scientific Reports (2016)
-
STAT3 selectively interacts with Smad3 to antagonize TGF-β
Oncogene (2016)